Januvia vs Jardiance
Side-by-side cost comparison based on Medicare Part D data
Januvia
Sitagliptin
Manufactured by Merck
Jardiance
Empagliflozin
Manufactured by Boehringer Ingelheim
Jardiance costs 4% less per claim than Januvia ($210.00 vs $219.00). A generic version of Jardiance is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Januvia | Jardiance |
|---|---|---|
| Avg Cost Per Claim | $219.00 | $210.00 |
| Total Medicare Spending | $2.7B | $3.9B |
| Total Beneficiaries | 1,560,000 | 2,150,000 |
| Total Claims | 12,480,000 | 18,760,000 |
| Annual Cost/Patient | $1,753.00 | $1,835.00 |
| Year-over-Year Change | -12.3% | +22.7% |
| Generic Available | No | Yes |
| Patent Expiration | Jul 17, 2026 | May 23, 2025 |
| Manufacturer | Merck | Boehringer Ingelheim |
| Condition | Diabetes | Diabetes |
| Generic Name | Sitagliptin | Empagliflozin |
Januvia vs Jardiance: What the Data Shows
Januvia (Sitagliptin) and Jardiance (Empagliflozin) are both used to treat diabetes. Based on Medicare Part D data, Jardiance costs $210.00 per claim, which is 4% less than Januvia at $219.00 per claim.
Medicare spent $2.7B on Januvia and $3.9B on Jardiance. In terms of patient reach, Jardiance serves more beneficiaries (2,150,000 vs 1,560,000).
Year-over-year spending changed -12.3% for Januvia and +22.7% for Jardiance. Jardiance saw significant spending growth, suggesting increased utilization or price increases.
Jardiance has a generic available, while Januvia remains brand-only until its patent expires Jul 17, 2026.
Frequently Asked Questions
Jardiance is cheaper at $210.00 per claim, compared to $219.00 for Januvia. That makes Jardiance about 4% less expensive per claim based on Medicare Part D data.
Yes, both Januvia and Jardiance are used to treat diabetes. Your doctor can help determine which medication is more appropriate for your specific situation.
Jardiance has a generic version (Empagliflozin) available, which is typically much cheaper. Januvia is currently brand-only, with patent expiring Jul 17, 2026.
Medicare Part D spent $2.7B on Januvia covering 1,560,000 beneficiaries, and $3.9B on Jardiance covering 2,150,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.